Antigenics Stock

Antigenics EBIT

The EBIT of Antigenics (ANTI) as of Aug 11, 2026 is -16.63 M USD.

EBIT

-16.63 MUSD

Last updated:

In 2026, Antigenics's EBIT was -16.63 M USD, a % increase from the - USD EBIT recorded in the previous year.

The Antigenics EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (undefined USD)
Date
EBIT (undefined USD)
Jan 1, 1993
0.00 base
Jan 1, 1994
0.00 base
Jan 1, 1995
0.00 base
Jan 1, 1996
0.00 base
Jan 1, 1997
0.00 base
Jan 1, 1998
0.00 base
Jan 1, 1999
0.00 base
Jan 1, 2000
0.00 base
YEAREBIT (undefined USD)
2000 -
1999 -
1998 -
1997 -
1996 -
1995 -
1994 -
1993 -
1992 -
1991 -
1990 -
Access this data via the Eulerpool API

Antigenics Revenue

Antigenics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 1993
50,000.00 USD
-6.32 M USD
-6.23 M USD
Jan 1, 1994
200,000.00 USD
-9.39 M USD
-9.05 M USD
Jan 1, 1995
1.25 M USD
-9.31 M USD
-17.43 M USD
Jan 1, 1996
2.67 M USD
-9.31 M USD
-8.03 M USD
Jan 1, 1997
841,000.00 USD
-15.79 M USD
-16.99 M USD
Jan 1, 1998
6.74 M USD
-19.41 M USD
-18.23 M USD
Jan 1, 1999
11.05 M USD
-15.09 M USD
-14.09 M USD
Jan 1, 2000
3.22 M USD
-16.63 M USD
-17.96 M USD

Antigenics Margins

Antigenics stock margins

The Antigenics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Antigenics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Antigenics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 1993
0.00 %
-12,640.00 %
-12,460.00 %
Jan 1, 1994
0.00 %
-4,695.00 %
-4,525.00 %
Jan 1, 1995
0.00 %
-746.31 %
-1,396.55 %
Jan 1, 1996
0.00 %
-348.58 %
-300.75 %
Jan 1, 1997
0.00 %
-1,877.88 %
-2,020.33 %
Jan 1, 1998
0.00 %
-288.11 %
-270.61 %
Jan 1, 1999
0.00 %
-136.57 %
-127.52 %
Jan 1, 2000
0.00 %
-516.71 %
-557.84 %

Antigenics Stock analysis

What does Antigenics do? Antigenics Inc, now Agenus Inc, is a biotechnology company specializing in the research and development of innovative therapies for cancer and infectious diseases. The company is headquartered in Lexington, Massachusetts. The history of Antigenics begins in the late 1980s when the founder, Garo Armen, developed a method for identifying DNA sequences that encode specific proteins. The approach was based on the isolation of lentiviral vectors from human cells, which were then used to transfer the DNA sequences to other cells. This method allowed Antigenics to identify a variety of tumor-specific antigens (TSA) that could serve as potential targets for immunotherapies. In the 1990s, Antigenics focused on developing anti-tumor vaccines based on TSA. The first product was Oncophage, a vaccine made from individual TSA peptides isolated from the patient's tumor cells. Oncophage was tested in Phase II clinical trials in patients with various forms of cancer, including melanoma, renal cell carcinoma, and glioblastoma. Although the vaccine showed significant survival benefits in some studies, it was not approved in the United States. Today, Oncophage is used in Russia and India for the treatment of kidney cancer. In the late 2000s, Antigenics expanded its portfolio to include other immune-oncology approaches such as immune checkpoint protein CTLA-4 modulators, cytotoxic antibodies against cancer cells, and small molecules for immune activation. In 2014, the company was renamed Agenus Inc to reflect its expanded business model. Today, Agenus focuses on the development of immune combination therapies that combine various approaches to activate and modulate the immune system to achieve synergistic effects. The focus is on the use of immune checkpoint inhibitors that relieve T-cell inhibition, as well as the combination of vaccines and cytotoxic antibodies. Agenus' current products include immune checkpoint inhibitor CTLA-4 Ig, which is being tested in Phase III clinical trials for melanoma and lung cancer, and the QS-21 vaccine, which elicits a strong immune response and is used as an adjuvant for other vaccines for the treatment of infectious diseases. Agenus has various divisions, including a division for veterinary immunotherapies, which specializes in the development of vaccines and treatment methods for dogs and horses with cancer. Overall, Agenus has a rich history in the research and development of immunotherapies for the treatment of cancer and infectious diseases. Although the company has experienced setbacks in the past, it remains a key player in the field of immune-oncology and is expected to develop further groundbreaking therapies. Antigenics is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Antigenics's EBIT

Antigenics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Antigenics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Antigenics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Antigenics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Antigenics stock

EBIT of Antigenics is -16.63 M USD in 2026.

On Eulerpool you can find the complete historical development of EBIT Antigenics since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Antigenics historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Antigenics

All Key Metrics — Antigenics